168 related articles for article (PubMed ID: 21208978)
1. Epstein-Barr virus-driven lymphoproliferative disorder post-CAMPATH-1H (alemtuzumab) in refractory polymyositis.
Cooles FA; Jackson GH; Menon G; Isaacs JD
Rheumatology (Oxford); 2011 Apr; 50(4):810-2. PubMed ID: 21208978
[No Abstract] [Full Text] [Related]
2. Epstein-Barr virus-induced lymphoproliferative disorder after rituximab combined with CHOP therapy.
Johnston A; Salles G; Espinouse D; Felman P; André P; Berger F; Coiffier B
Clin Lymphoma Myeloma; 2008 Dec; 8(6):356-8. PubMed ID: 19064401
[TBL] [Abstract][Full Text] [Related]
3. Burkitt post-transplantation lymphoma in adult solid organ transplant recipients: sequential immunochemotherapy with rituximab (R) followed by cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or R-CHOP is safe and effective in an analysis of 8 patients.
Zimmermann H; Reinke P; Neuhaus R; Lehmkuhl H; Oertel S; Atta J; Planker M; Gärtner B; Lenze D; Anagnostopoulos I; Riess H; Trappe RU
Cancer; 2012 Oct; 118(19):4715-24. PubMed ID: 22392525
[TBL] [Abstract][Full Text] [Related]
4. Lymphomatoid granulomatosis treated with rituximab and chemotherapy.
Rao R; Vugman G; Leslie WT; Loew J; Venugopal P
Clin Adv Hematol Oncol; 2003 Nov; 1(11):658-60; discussion 660. PubMed ID: 16258464
[No Abstract] [Full Text] [Related]
5. Durable remission after aggressive chemotherapy for very late post-kidney transplant lymphoproliferation: A report of 16 cases observed in a single center.
Mamzer-Bruneel MF; Lomé C; Morelon E; Levy V; Bourquelot P; Jacobs F; Gessain A; Mac Intyre E; Brousse N; Kreis H; Hermine O
J Clin Oncol; 2000 Nov; 18(21):3622-32. PubMed ID: 11054435
[TBL] [Abstract][Full Text] [Related]
6. Monitoring for cytomegalovirus and Epstein-Barr virus infection in chronic lymphocytic leukemia patients receiving i.v. fludarabine-cyclophosphamide combination and alemtuzumab as consolidation therapy.
Orlandi EM; Baldanti F; Citro A; Pochintesta L; Gatti M; Lazzarino M
Haematologica; 2008 Nov; 93(11):1758-60. PubMed ID: 18790800
[No Abstract] [Full Text] [Related]
7. Alemtuzumab (Campath-1H) for treatment of refractory polymyositis.
Thompson B; Corris P; Miller JA; Cooper RG; Halsey JP; Isaacs JD
J Rheumatol; 2008 Oct; 35(10):2080-2. PubMed ID: 18843768
[No Abstract] [Full Text] [Related]
8. Successful treatment of a child with late-onset T-cell post-transplant lymphoproliferative disorder/lymphoma.
Williams KM; Higman MA; Chen AR; Schwartz CL; Wharam M; Colombani P; Arceci RJ
Pediatr Blood Cancer; 2008 Mar; 50(3):667-70. PubMed ID: 17318876
[TBL] [Abstract][Full Text] [Related]
9. Assessing the risk of epstein-barr virus-related lymphoproliferative disorders before administration of visilizumab.
Guthery SL; Gross TG
Gastroenterology; 2008 Mar; 134(3):895-6. PubMed ID: 18325408
[No Abstract] [Full Text] [Related]
10. Leukocytoclastic vasculitis as early manifestation of Epstein-Barr virus-positive diffuse large B-cell lymphoma of the elderly.
Zoroquiain P; González S; Molgó M; Rodríguez A; Valbuena JR
Am J Dermatopathol; 2012 May; 34(3):330-4. PubMed ID: 22197862
[TBL] [Abstract][Full Text] [Related]
11. Aggressive posttransplant lymphoproliferative disease in a renal transplant patient treated with alemtuzumab.
Muzaffar M; Taj A; Ratnam S
Am J Ther; 2010; 17(6):e230-3. PubMed ID: 19918163
[TBL] [Abstract][Full Text] [Related]
12. Post-transplantation lymphoproliferative disorder of recipient origin in a boy with acute T-cell leukemia with detection of B-cell clonality 3 months before stem cell transplantation.
Kontny U; Boppana S; Jung A; Goebel H; Strahm B; Peters A; Dormann S; Werner M; Bader P; Fisch P; Niemeyer C
Haematologica; 2005 Nov; 90 Suppl():ECR27. PubMed ID: 16266918
[TBL] [Abstract][Full Text] [Related]
13. Post-transplant lymphoproliferative disease following reduced intensity conditioning transplants incorporating alemtuzumab.
Bokhari S; Das-Gupta E; Russell N; Byrne J
Bone Marrow Transplant; 2008 Aug; 42(4):281-2. PubMed ID: 18490912
[No Abstract] [Full Text] [Related]
14. [Epstein-Barr virus related B-cell lymphoproliferative disorder complicated with bone marrow fibrosis, which was successfully treated with 2 courses of CHOP regimen].
Hagihara M; Watanabe S; Suyama T; Sato K
Rinsho Ketsueki; 2005 Oct; 46(10):1129-35. PubMed ID: 16440776
[TBL] [Abstract][Full Text] [Related]
15. EBV+ lymphoproliferative disease following prolonged chemotherapy for refractory LCH.
Lee DA; Tatevian N; Herring RA; McClain KL
Pediatr Blood Cancer; 2008 Mar; 50(3):728-30. PubMed ID: 17243127
[TBL] [Abstract][Full Text] [Related]
16. Spectrum of infection, risk and recommendations for prophylaxis and screening among patients with lymphoproliferative disorders treated with alemtuzumab*.
Thursky KA; Worth LJ; Seymour JF; Miles Prince H; Slavin MA
Br J Haematol; 2006 Jan; 132(1):3-12. PubMed ID: 16371014
[TBL] [Abstract][Full Text] [Related]
17. Low serum albumin level is associated with cytomegalovirus reactivation in patients with chronic lymphoproliferative diseases treated with alemtuzumab (Campath-1H)-based therapies.
Borthakur G; Lin E; Faderl S; Ferrajoli A; Wierda W; Giles F; Browning ML; Kantarjian H; Keating M; O'Brien S
Cancer; 2007 Dec; 110(11):2478-83. PubMed ID: 17960607
[TBL] [Abstract][Full Text] [Related]
18. Fatal EBV-related post-transplant lymphoproliferative disorder (LPD) after matched related donor nonmyeloablative peripheral blood progenitor cell transplant.
Zamkoff KW; Bergman S; Beaty MW; Buss DH; Pettenati MJ; Hurd DD
Bone Marrow Transplant; 2003 Feb; 31(3):219-22. PubMed ID: 12621485
[TBL] [Abstract][Full Text] [Related]
19. An EBV-positive lymphoproliferative disorder after therapy with alemtuzumab.
Ghobrial IM; Otteman LA; White WL
N Engl J Med; 2003 Dec; 349(26):2570-2; discussion 2570-2. PubMed ID: 14695424
[No Abstract] [Full Text] [Related]
20. [A case of effective use of alemtuzumab in a male patient with T-cell lymphoma].
Sokolov AH; Parovichnikova EN; Isaev VG; Ustinova EN; Shavlokhov VS; Atopkov VA; Model SV; Tsyba NN; Kaplanskaia IB; Kliasova GA; Aleksanian MZh; Vishnevskaia ES; Togonidze DK; Mirzoian EE; Savchenko VG
Ter Arkh; 2004; 76(12):73-5. PubMed ID: 15724932
[No Abstract] [Full Text] [Related]
[Next] [New Search]
